| Indications | • adjunctive therapy to diet to reduce elevated total cholesterol (total C), LDL, apolipoprotein B (ApoB), non-HDL, and TG levels and to increase HDL in adults with primary hyperlipidemia or mixed dyslipidemia.
• adjunctto reduce total C, LDL and ApoB levels in adolescents.
• Who are at least 1 year after menarchy (women), 10 to 17 years with heterozygous familial hypercholesterolemia (HeFH) and in those who, after dietary treatment, have an LDL >190mg/dl or.
• >160mg/dl and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors.
• For the treatment of hypertriglyceridemia in adults.
• For the treatment of primary dysbetalipoproteinemia (type III hyperlipoproteinemia).
•Adjunct therapy to other lipid-lowering treatments (e.g., LDL Apheresis) or alone if such treatments are not available to reduce LDL, total C, and ApoB in adults with hypercholesterolemia homozygous familial (HoFH).
• Adjunct to slow the progression of atherosclerosis in adults as
• Part of a treatment strategy aimed at lowering total C and LDL to target levels.
• Reduces the risk of myocardial infarction, stroke and artery Revascularization procedures in people at increased risk of cardiovascular disease. |
|---|
